BioSpace News Archive

Ninth GPCR-targeted drug candidate overall generated from Sosei Heptares’ StaR® technology/SBDD platform to enter clinical development

APEIRON Biologics AG announced the next development steps for APN01 for the treatment of COVID-19.

Unified application suites for clinical, regulatory, quality, and safety eliminate siloes to increase efficiency and improve compliance

Ethypharm announces that it has acquired the exclusive rights for the development, registration and commercialization in the top 5 European markets of a novel celecoxib formulation already approved in the US for the acute treatment of migraine.

POXEL SA, a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis announced the publication of the meeting notice for the Annual General Meeting, which will take place in a closed virtual session on June 23rd, 2021 at 1.00pm CEST.

Clinical Research Organization, Accerise Inc., Has Been Retained To Work With RepliCel and Its Other Service Providers To Prepare Study Documentation, Plans, and Approvals for Clinical Evaluation by Multiple Clinical Sites in Japan

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that it received a communication from the Division of Neurology Products 1 (“Division”) of the U.S. Food and Drug Administration (“FDA”)

Landos Biopharma, Inc (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced the appointment of Tim M. Mayleben to its Board of Directors.

Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced two poster presentations at the International Society for Pharmacoeconomics and Outcomes Research

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company’s management will participate in Cowen’s 2nd Annual Virtual Oncology Innovation Summit. MacroGenics’ management will participate in a fireside chat with the analyst on Thursday, May 20, 2021, at 9:20 am ET.